Biogen (BIIB) Misses Q4 EPS by 1c, ADUHELM Sales Just $1 Million ; Lowers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Oil slips as Saudi Arabia offers more crude via Oman
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
Biogen (BIIB) PT Lowered to $290 at Needham & Company
February 4, 2022 6:26 AM ESTNeedham & Company analyst Ami Fadia lowered the price target on Biogen (NASDAQ: BIIB) to $290.00 (from $292.00) while maintaining a Buy rating.
The analyst commented, "BIIB pulled back ~2% following lower-than-expected 2022 guidance as we await visibility into Aduhelm's final coverage decision in April. Irrespective, it... More
Biogen (BIIB) PT Lowered to $304 at Stifel
February 3, 2022 11:12 AM ESTStifel analyst Paul Matteis lowered the price target on Biogen (NASDAQ: BIIB) to $304.00 (from $344.00) while maintaining a Buy rating following earnings.
The analyst commented, "Biogen's 4Q21 earnings call was fundamentally a non-event, as few specifics were offered on whether there's a feasible... More
